Published in Transplant Proc on February 01, 1993
What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg (1999) 1.02
Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol (1999) 0.96
Tacrolimus (FK506)-Associated Renal Pathology. Adv Anat Pathol (1997) 0.90
Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. Clin Transplant (1997) 0.90
Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. Br J Pharmacol (1999) 0.86
FK506 in solid organ transplantation. Ther Drug Monit (1995) 0.85
The role of environmental factors in insulin-dependent diabetes mellitus: an unresolved issue. Environ Health Perspect (1999) 0.84
Recent advances in hepatic transplantation at the University of Pittsburgh. Clin Transpl (1993) 0.83
Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother (2010) 0.81
Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). Br J Clin Pharmacol (1994) 0.81
Late onset tacrolimus-induced life-threatening polyneuropathy in a kidney transplant recipient patient. Clin Kidney J (2012) 0.78
A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients. J Biomed Res (2013) 0.77
Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. Br J Clin Pharmacol (2000) 0.76
Acute demyelinating polyneuropathy after lung transplantation: guillain-barré syndrome or tacrolimus toxicity? Case Rep Transplant (2014) 0.75
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
Kidney transplantation under FK 506. JAMA (1990) 7.45
A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature (1989) 7.02
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Transplantation. JAMA (1990) 1.71
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56
Acute and chronic renal failure in liver transplantation. Nephron (1990) 1.52
Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41
Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Neurologic complications of FK 506. Transplant Proc (1991) 1.34
Long-term use of cyclosporin in liver grafting. Q J Med (1985) 1.24
Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. Hepatology (1991) 1.13
The spectrum of ciclosporin nephrotoxicity. Am J Nephrol (1990) 1.05
Immunophilin-ligand complexes as probes of intracellular signaling pathways. Transplant Proc (1991) 1.05
Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation (1990) 1.04
The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. Transplantation (1992) 0.98
Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc (1991) 0.80
Conversion from standard cyclosporine to low-dose cyclosporine in liver transplant recipients: effect on nephrotoxicity and hypertension beyond one year. Transplant Proc (1989) 0.80
Conversion from standard cyclosporine to low-dose cyclosporine and azathioprine therapy as treatment for cyclosporine-related complications in liver transplant patients. Transplant Proc (1987) 0.79
Evolution of liver transplantation. Hepatology (1982) 19.54
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
Kidney transplantation under FK 506. JAMA (1990) 7.45
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Liver transplantation (1). N Engl J Med (1989) 4.53
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol (1999) 3.75
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
De novo malignant tumors in organ transplant recipients. Transplant Proc (1971) 3.03
Experience with 150 liver resections. Ann Surg (1983) 3.01
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01